Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) was downgraded by investment analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a report released on Thursday,Zacks.com reports. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have given a Hold rating to the company. Get Chugai Pharmaceutical alerts:View Our Latest Research Report on CHGCYChugai Pharmaceutical Stock PerformanceShares of CHGCY opened at $21.66 on Thursday.